228418-45-9

Basic information

• Product Name: Methyl 2-nitro-4-(trifluoromethyl)benzoate
• Synonyms: Benzoic acid, 2-nitro-4-(trifluoroMethyl)-, Methyl ester;4-(Methoxycarbonyl)-3-nitrobenzotrifluoride, Methyl 2-nitro-alpha,alpha,alpha-trifluoro-p-toluate
• CAS NO: 228418-45-9
• Molecular Formula: C₉H₆F₃NO₄
• Molecular Weight: 249.143
• Product Categories: Fluorine series
• Mol File: 228418-45-9.mol

Chemical Properties

• Boiling Point: 272℃
• Flash Point: 118℃
• Appearance: /
• Density: 1.442
• Vapor Pressure: 0.0063mmHg at 25°C
• Refractive Index: 1.485
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: Methyl 2-nitro-4-(trifluoromethyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-nitro-4-(trifluoromethyl)benzoate(228418-45-9)
• EPA Substance Registry System: Methyl 2-nitro-4-(trifluoromethyl)benzoate(228418-45-9)

Safety Data

• Hazardous Substances Data: 228418-45-9(Hazardous Substances Data)

Usage

Uses

Methyl 2-Nitro-4-(trifluoromethyl)benzoate has been used in the synthesis of isoxazolinone antibacterial agents, using nitrogen as a replacement for the stereogenic center of the molecule. Also used in the preparation of benzo[b]azepines as inhibitors of cholesterol ester transfer.n

InChI:InChI=1/C9H6F3NO4/c1-17-8(14)6-3-2-5(9(10,11)12)4-7(6)13(15)16/h2-4H,1H3

Upstream product

• 67-56-1 methanol 
• 22227-55-0 2-nitro-4-trifluoromethyl benzamide 
• 1445-45-0 Trimethyl orthoacetate 
• 320-94-5 2-nitro-4-trifluoromethylbenzoic acid 
• 201230-82-2 carbon monoxide 
• 121-17-5 2-chloro-3-nitro-5-trifluoromethylbenzene 
• 349-03-1 1-bromo-4-trifluoromethyl-2-nitrobenzene 
• 74-88-4 methyl iodide 

Downstream Products

• 61500-87-6 methyl 2-Amino-4-(trifluoromethyl)benzoate 
• 913299-79-3 methyl 2-(acetylamino)-3-nitro-4-(trifluoromethyl)benzoate 
• 913299-80-6 methyl 2-amino-3-nitro-4-(trifluoromethyl)benzoate 
• 913299-81-7 methyl 2,3-diamino-4-(trifluoromethyl)benzoate 
• 869550-68-5 methyl 2-(acetylamino)-4-(trifluoromethyl)benzoate 
• 192805-69-9 methyl 2-methylmercapto-4-(trifluoromethyl)benzoate 

Relevant articles and documents

Pyrazole derivative for FGFR inhibitor and preparation method of pyrazole derivative

The invention provides a pyrazole derivative for an FGFR inhibitor and a preparation method of the pyrazole derivative. The invention specifically relates to an amide pyrazole compound serving as an FGFR irreversible inhibitor, and a preparation method and application thereof. The present invention provides a compound as shown in Formula I, or a pharmaceutically acceptable salt, or solvate, isotope substitute, prodrug, or metabolite thereof. The compound as shown in general formula I have FGFR inhibitory activity, and is capable of preventing or treating disorders associated with FGFR activityor expression, preferably such as cancer.

Preparation method of 1-cyclopropyl-3-(2-methylthio-4-trifluoromethylphenyl)propyl-1,3-dione

The invention provides a preparation method of 1-cyclopropyl-3-(2-methylthio-4-trifluoromethylphenyl)propyl-1,3-dione, and belongs to the technical field of organic synthesis. The preparation method comprises following steps: (1) mixing 2-nitro-4-trifluor

Preparation method of methyl 2-nitryl-4-trifluoromethyl benzoate

The invention discloses a preparation method of methyl 2-nitryl-4-trifluoromethyl benzoate, belongs to the technical field of organic synthesis, and solves the technical problem that a new method forpreparing the methyl 2-nitryl-4-trifluoromethyl benzoate is provided. The method comprises the following steps: performing alkali catalytic or acid catalytic hydrolysis on 2-nitryl-4-trifluoromethyl benzonitrile to prepare 2-nitryl-4-trifluoromethyl phenyl methyl amide; mixing the 2-nitryl-4-trifluoromethyl phenyl methyl amide with a sulfuric acid-methanol solution and performing alcoholysis reaction to obtain the methyl 2-nitryl-4-trifluoromethyl benzoate. The method disclosed by the invention has the advantages of mild reaction conditions and simple post-processing; moreover, the high-puritymethyl 2-nitryl-4-trifluoromethyl benzoate can be obtained in a form of high yield, and realization of industrial production is facilitated.

Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Novel Heterocyclidene Acetamide Derivative

A compound represented by formula (I′): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group,

NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE

A compound represented by formula (I'): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group,

FUSED HETEROCYCLIC COMPOUNDS

There is provided a CRF receptor antagonist comprising a compound of the formula (I) : wherein R1 is an optionally substituted hydrocarbyl, an optionally substituted C-linked heterocyclic group, an optionally substituted N-linked heteroaryl group, a cyano

COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA

Compounds of Formula (I): wherein n, m, p, q, Y, R1 R2, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.

Quinoxaline compounds

Certain amidophenyl-sulfonylamino-quinoxaline compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.

INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.